Newron Pharmaceuticals
Update in progressNWRN.SW (Swiss)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Newron Pharmaceuticals S.p.A. is an Italian biopharma company focused on nervous system diseases in Italy and the United States. Its approved drug Xadago (safinamide) treats Parkinson’s disease in the EU, UK, US, Latin America, Switzerland and Japan. Its lead candidate Evenamide targets schizophrenia and treatment‑resistant schizophrenia in Phase III, and Ralfinamide targets rare neuropathic pain. It partners with Zambon and Meiji Seika Pharma for safinamide. Founded 1999, headquartered in Bresso, Italy.
Company score
- Sentiment
- -0.06
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- -0.14
- Governance
- -0.10
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.06
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.06
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!